- ICH GCP
- EU-Register für klinische Studien
Neueste Versuche
EudraCT Number: 2011-001692-39 | Sponsor Protocol Number: CFTY720DDE06 | Start Date: | ||||||||||||||||
Sponsor Name: Novartis Pharma GmbH | ||||||||||||||||||
Full Title: A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS pa... | ||||||||||||||||||
Medical condition: Multiple Sclerosis Depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003575-47 | Sponsor Protocol Number: BP21572 | Start Date: | |||||||||||
Sponsor Name: F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multipl... | |||||||||||||
Medical condition: Patients with Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002261-38 | Sponsor Protocol Number: P100504 | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000358-11 | Sponsor Protocol Number: CAMN107DDE06 | Start Date: | |||||||||||
Sponsor Name: Novartis Pharma GmbH | |||||||||||||
Full Title: An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatment | |||||||||||||
Medical condition: metastatic or unresectable gastrointestinal stromal tumor | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) FI (Completed) IT (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003795-36 | Sponsor Protocol Number: CERL080ADE27 | Start Date: | |||||||||||
Sponsor Name: Novartis Pharma GmbH | |||||||||||||
Full Title: Multi-center, open-label, prospective, randomized, parallel group study investigating a tacrolimus Hexal® based regimen versus a Prograf® based regimen in de novo renal transplant recipients | |||||||||||||
Medical condition: renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000728-97 | Sponsor Protocol Number: EMR200109_635 | Start Date: | |||||||||||
Sponsor Name: Academic MS Center Limburg | |||||||||||||
Full Title: Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001546-17 | Sponsor Protocol Number: GBG40 | Start Date: | ||||||
Sponsor Name: German Breast Group | ||||||||
Full Title: GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary brea... | ||||||||
Medical condition: Primary breast cancer | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001721-34 | Sponsor Protocol Number: 20050197 | Start Date: | |||||||||||
Sponsor Name: Amgen Inc | |||||||||||||
Full Title: A Phase 2, Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Darbepoetin alfa for the Treatment of Anemia in Paediatric Subjects with Solid Tumours Receiving Cyclic Chemotherapy | |||||||||||||
Medical condition: Chemotherapy-induced anemia (CIA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017274-20 | Sponsor Protocol Number: 0927 | Start Date: | ||||||
Sponsor Name: Centre Hospitalier Universitaire de GRENOBLE | ||||||||
Full Title: Evaluation de l’efficacité de l’Alfentanil chez l’enfant en réanimation infantile par rapport au Sufentanil - traitement de référence - sur le confort du patient lors de l’aspiration trachéale | ||||||||
Medical condition: confort de l'enfant lors de l'aspiration trachéale en réanimation pédiatrique | ||||||||
|
||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: FR (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002923-24 | Sponsor Protocol Number: R033812GTS3001 | Start Date: | |||||||||||
Sponsor Name: Janssen-Cilag International NV | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects Wi... | |||||||||||||
Medical condition: Nausea and Vomiting Due to Acute Gastroenteritis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PT (Completed) BE (Completed) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |